[go: up one dir, main page]

TNSN07200A1 - Dibenzylamines et derives - Google Patents

Dibenzylamines et derives

Info

Publication number
TNSN07200A1
TNSN07200A1 TNP2007000200A TNSN07200A TNSN07200A1 TN SN07200 A1 TNSN07200 A1 TN SN07200A1 TN P2007000200 A TNP2007000200 A TN P2007000200A TN SN07200 A TNSN07200 A TN SN07200A TN SN07200 A1 TNSN07200 A1 TN SN07200A1
Authority
TN
Tunisia
Prior art keywords
cholesterol
levels
certain
dibenzylamines
derivatives
Prior art date
Application number
TNP2007000200A
Other languages
English (en)
Inventor
George Chang
Mary Theresa Didiuk
Peter Hans Dorff
Ravi Shanker Garigipati
Wenhua Jiao
Bruce Allen Lefker
David Austen Perry
Roger Benjamin Ruggeri
Toby James Underwood
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN07200A1 publication Critical patent/TNSN07200A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Dibenzylamines et dérivés, compositions pharmaceutiques contenant ces composés et utilisation de ces composés pour élever les taux de certains lipides plasmatiques, comprenant le cholestérol-liprotéines haute densité, et pour abaisser les taux plasmatiques de certains autres lipides, tels que le cholestérol-LDL et les triglycérides, et, en conséquence, pour traiter des maladies qui sont exacerbées par des taux bas de cholestérol-HDL et/ou des taux élevés de cholestérol-LDL et triglycérides, telles que l'athérosclérose et des maladies cardiovasculaires chez certains mammifères, y compris les êtres humains.
TNP2007000200A 2004-11-23 2007-05-22 Dibenzylamines et derives TNSN07200A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63043404P 2004-11-23 2004-11-23
US71561705P 2005-09-12 2005-09-12
PCT/IB2005/003500 WO2006056854A1 (fr) 2004-11-23 2005-11-21 Composes et derives de dibenzyl amine

Publications (1)

Publication Number Publication Date
TNSN07200A1 true TNSN07200A1 (fr) 2008-11-21

Family

ID=35828305

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000200A TNSN07200A1 (fr) 2004-11-23 2007-05-22 Dibenzylamines et derives

Country Status (22)

Country Link
US (1) US20090239865A1 (fr)
EP (1) EP1817297A1 (fr)
JP (1) JP2008520645A (fr)
KR (1) KR20070069213A (fr)
AP (1) AP2007003980A0 (fr)
AR (1) AR053784A1 (fr)
AU (1) AU2005308584A1 (fr)
BR (1) BRPI0518476A2 (fr)
CA (1) CA2589322A1 (fr)
CR (1) CR9089A (fr)
EA (1) EA200700924A1 (fr)
GT (1) GT200500339A (fr)
IL (1) IL183133A0 (fr)
MA (1) MA29039B1 (fr)
MX (1) MX2007006137A (fr)
NL (1) NL1030486C2 (fr)
NO (1) NO20073025L (fr)
PE (1) PE20061124A1 (fr)
TN (1) TNSN07200A1 (fr)
TW (1) TW200630350A (fr)
UY (1) UY29222A1 (fr)
WO (1) WO2006056854A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2007075194A1 (fr) * 2005-12-28 2007-07-05 Reddy Us Therapeutics, Inc. Derives de benzylamine selectifs et leur utilite en tant qu’inhibiteurs de la proteine de transfert de l'ester de cholesterol
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2007041494A2 (fr) * 2005-09-30 2007-04-12 Merck & Co., Inc. Inhibiteurs de la proteine de transfert des esters de cholesterol
CA2634833A1 (fr) * 2005-12-29 2007-07-05 Novartis Ag Derives de pyridinyle amine en tant qu'inhibiteurs de la proteine de transfert d'ester cholesterylique (cetp)
UY30117A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
AR060873A1 (es) 2006-05-10 2008-07-16 Novartis Ag Derivados biciclicos como inhibidores de cetp
CA2650515A1 (fr) * 2006-05-11 2007-11-22 Novartis Ag Derives de la benzylamine en tant qu'inhibiteurs de la cetp
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
CN101679309B (zh) * 2007-04-13 2012-02-29 兴和株式会社 具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
EP2222638A2 (fr) * 2007-11-21 2010-09-01 Decode Genetics EHF Inhibiteurs de pde4 biaryle pour traiter une inflammation
EP2222639A1 (fr) * 2007-11-21 2010-09-01 Decode Genetics EHF Inhibiteurs de biaryle pde4 pour le traitement de troubles pulmonaires et cardiovasculaires
ES2566739T3 (es) * 2008-02-01 2016-04-15 Brickell Biotech, Inc. Aminoalquilbifenilo N,N-disustituidos antagonistas de receptores de prostaglandina D2
EP2245002A4 (fr) * 2008-02-01 2011-08-17 Amira Pharmaceuticals Inc Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
WO2009108720A2 (fr) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonistes des récepteurs d2 de la prostaglandine
JP2011518130A (ja) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (fr) * 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Antagonistes d’hétéroaryle des récepteurs de la prostaglandine d2
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
WO2010059838A2 (fr) * 2008-11-20 2010-05-27 Decode Genetics Ehf Inhibiteurs de pde4 sélectifs pour la forme longue de pde4 pour traiter une inflammation et éviter des effets secondaires
CA2768587A1 (fr) 2009-08-05 2011-02-10 Panmira Pharmaceuticals, Llc Antagoniste de dp2 et ses utilisations
PH12012501349A1 (en) 2010-01-06 2013-01-14 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
US9867811B2 (en) * 2011-07-08 2018-01-16 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
IN2014CN02290A (fr) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
US9717714B2 (en) 2012-12-19 2017-08-01 Merck Sharp & Dohme Corp. Spirocyclic CETP inhibitors
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
CN115677572B (zh) * 2021-07-29 2024-05-28 武汉思瓴生物科技有限公司 氟代酰胺类衍生物、药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438551A1 (fr) * 2001-02-15 2002-08-22 Pfizer Products Inc. Agonistes des ppar
JP2003221376A (ja) * 2001-11-21 2003-08-05 Japan Tobacco Inc Ｃｅｔｐ活性阻害剤
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
CA2562082C (fr) * 2004-04-13 2013-06-25 Merck & Co., Inc. Inhibiteurs de la cetp pour le traitement et la prevention de l'atherosclerose

Also Published As

Publication number Publication date
TW200630350A (en) 2006-09-01
AP2007003980A0 (en) 2007-06-30
UY29222A1 (es) 2006-06-30
PE20061124A1 (es) 2006-10-13
CR9089A (es) 2007-05-30
AR053784A1 (es) 2007-05-23
CA2589322A1 (fr) 2006-06-01
MX2007006137A (es) 2007-07-19
IL183133A0 (en) 2007-09-20
NO20073025L (no) 2007-08-20
EP1817297A1 (fr) 2007-08-15
BRPI0518476A2 (pt) 2008-11-18
GT200500339A (es) 2006-06-22
MA29039B1 (fr) 2007-11-01
US20090239865A1 (en) 2009-09-24
KR20070069213A (ko) 2007-07-02
AU2005308584A1 (en) 2006-06-01
NL1030486C2 (nl) 2006-10-24
NL1030486A1 (nl) 2006-05-24
WO2006056854A1 (fr) 2006-06-01
EA200700924A1 (ru) 2007-10-26
JP2008520645A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
TNSN07200A1 (fr) Dibenzylamines et derives
MA30272B1 (fr) Derives de dibenzylamines servant d'inhibiteurs de cetp.
MA27532A1 (fr) Piperidines a substituant phenyle, destinees a etre utilisees comme activateurs de ppar
TNSN06447A1 (fr) Composes heteroaryle et phenylsulfamoyle substitues
TNSN07100A1 (fr) Derives de 1, 2, 3, 4- tetrahydroquinoleine substitues en position 2 et a substituant 4-amino
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
TR200300594T2 (tr) Plazma lipoprotein(a)'yı ve kardiyovasküler hastalıkların risk faktörlerini azaltmak için terkipler ve yöntemler
BRPI0508584A (pt) lipìdio estruturado contendo composições e métodos com caracterìsticas promotoras de saúde e nutrição
ATE514345T1 (de) Zusammensetzung zur senkung des blutcholesterolspiegels
TNSN04164A1 (fr) Inhibiteurs de acc.
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
PL405074A1 (pl) Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów trójglicerydów
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
ATE332887T1 (de) Naturstoffe und deren derivate zur prävention und behandlung von herzkreislauf-, leber- und nierenerkrankungen und für kosmetische anwendungen
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA27311A1 (fr) Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
MA31754B1 (fr) Cis-imidazolines chirales
EP1315506A4 (fr) Derives phospholipides de l'acide valproique et leurs melanges